MENU

EXHIBITS

The IASLC 2022 World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. Over 7,000 clinicians and scientists from around the world are expected to attend. Increase your visibility and organization’s profile by becoming a Sponsor and/or Exhibitor or by holding an Industry Supported Symposium at this outstanding and important Conference.

Floor Plan

Confirmed Exhibitors

Amgen Inc

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Amoy Diagnostics Co., Ltd.

Amoy Diagnostics Co., Ltd. (SZSE: 300685) is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit www.amoydiagnostics.com.

Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Astrazeneca

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Blueprint Medicines

Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and hematologic disorders.

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.

Caris Life Sciences

Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).

Context Flow / RevealDx

contextflow is your comprehensive solution for all things lung CT: ILD, COPD, and lung cancer. Its clinical decision support system (SEARCH Lung CT), offers quantitative and qualitative analysis of 8 key image patterns and lung nodule detection, segmentation and quantification. By integrating new technology from partner RevealDx, nodules can be further characterized, detecting lung cancer earlier and reducing costs (publication forthcoming). contextflow SEARCH Lung CT includes a TIMELINE feature that even quantifies and visualizes nodules over time, allowing physicians to follow treatment progress easily and efficiently. Fully integrated into the radiologist's workflow, our preliminary research shows average reading time is 31% shorter when contextflow SEARCH Lung CT is available for use (publication forthcoming). See beyond a single case at contextflow.com.

Coreline Soft Co., Ltd.

Coreline Soft Ltd. was founded in the year 2012 and has its headquarter in Seoul, South Korea.
In September 2020 we founded Coreline Europe in Frankfurt, Germany in order to support the fast-growing European business.
Coreline develops AI based thorax specialized imaging diagnosis package, lung cancer screening (LCS), COPD quantification, and coronary artery calcification (CAC). These modules, so called “Big3”, cover the three big diseases of thoracic imaging.
More complex lung modules are part of our portfolio as well, such as texture analysis for ILD/IPF and unique pneumonia detection software including COVID-19.
Coreline became official solution provider of 4-IN-THE-LUNG-RUN (4ITLR) project, initiated and led by the Nelson Team (Erasmus MC and iDNA in the Netherlands). 4-IN-THE-LUNG-RUN has set up the goal to establish strategies that lead to cost-efficient lung cancer screening within reach for Europe.
Coreline also became the official solution provider for the largest German LCS Study, HANSE Study in Germany initiated by Medizinische Hochschule Hannover- MHH. Besides MHH, there are two additional hospitals taking part in this study: Lungenclinic Grosshansdorf and University Hospital Schleswig-Holstein am Campus Lübeck.
Another remarkable reference where Coreline´s software was chosen is K-LUKAS, Korean Lung Cancer Screening Project. Korea is the second country, followed by USA to adopt the national lung cancer screening program. The Full-Out Screening, started in 2019, involves 270 thousand examinees per year and 300 hospitals.
Most recent achievement for Coreline is beginning to work for the Italian Lung Screening Project (ILSP).
Coreline´s goal is not only to contribute to the field of treatment and management, but ideally to the area of prevention and diagnosis also.

Daiichi Sankyo, Inc.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

DaSH Global

DaSH Global supports the drug approval process through the power of delivering cost-efficient, timely and precise evidence from unique real-world research methodologies. Specialising in MedTech strategies & products through our vision of building collaborative ‘disruptive’ transformational research platforms from ‘joined up’ health care.
DaSH Global has launched the Digital Assessment Xchange (DAX) research platform in Lung Cancer & Mesothelioma.

Eli Lilly And Company

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.

Exelixis

Exelixis is an oncology-focused biotechnology company striving to accelerate discovery, development, and commercialization of new products for difficult-to-treat cancers. Clinical development focuses on continued evaluation of approved products and investigational pipeline. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.

Global Lung Cancer Coalition

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

GSK

GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

Janssen Pharmaceuticals

At Janssen Oncology, our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those living with cancer begins with a very considered step forwards. Whether it’s finding a novel solution, a new indication approval, or even just reaching one more patient. That’s The Power of Purpose™.

KRAS Kickers

KRAS Kickers is a patient founded organization that connects people to current research, resources, and community to kick cancer’s KRAS. KRAS Kickers operates under the Dusty Joy Foundation, a 501(c)(3) nonprofit organization with the mission of advancing education, early detection, optimal care, and empathy to people impacted by lung cancer and other cancers triggered by specific biomarkers.
Terri Conneran, who has been battling lung cancer since 2017, founded KRAS Kickers to create a network for patients and families in search of KRAS information and support. KRAS Kickers focuses on people with any KRAS oncogene cancer including patients, survivors, and all who care. Within KRAS Kickers, members engage with leading doctors, researchers, and advocates, build community, and share their stories to give hope to all with a KRAS biomarker.
The KRAS Kickers community believes that hope shared is hope multiplied. The organization actively monitors and shares KRAS-related research developments, information, and clinical trials to help patients find answers, explore treatment options, and connect with others on a similar journey. To learn more about KRAS Kickers, visit KRASKickers.org, connect on Facebook, or join the conversation on Twitter.

Lung Ambition Alliance

The Lung Ambition Alliance is a global coalition with the bold ambition to eliminate lung cancer as a cause of death. Its programs are funded directly and in kind by AstraZeneca, GLCC, Guardant Health, and IASLC.
By bridging between the commercial and non-profit sectors, we can bend the survival curve faster and improve outcomes. Our diverse perspectives help us identify and target needs more precisely, while our depth of resources amplify our impact.

Lung Cancer Europe

LuCE is the voice of Europeans impacted by lung cancer with a core purpose to Represent common interests of the lung cancer patient community in Europe.
We Collaborate with members and other stakeholders to Strengthen the voice of the lung cancer patient community and work to destigmatising the disease to ensure that those impactad by lung cancer get the care they need to achieve the best possible outcomes. We Act to address common problems by mobilising and leading collective action together with LuCE members, empowering them to ensure strong and effective lung cancer patient advocacy and to Amplify the patient voice by collaborating with all stakeholders with the power to improve the lives of people affected by lung cancer across Europe.
As a community we prioritise the needs and interests of those living with lung cancer, by working together to drive the changes needed to improve lung cancer outcomes. Our solidarity creates a strong community that is committed to helping each other achieve our common goals and to be as representative as possible of the European lung cancer patient community
Our organizational values ensure that we work in a professional, respectful, ethical manner with integrity and are accountable for all that we do.

Medscape LLC

Medscape is the leading source of clinical news, health information, medical education and point-of-care tools for health care professionals across more than 30 specialty areas. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools.

Merck Kgaa Darmstadt, Germany

Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at www.merckgrouponcology.com.

Mesothelioma UK

Mesothelioma UK is the national charity for anyone affected by mesothelioma. We exist to support people with mesothelioma to live better and live longer and to prevent mesothelioma happening to future generations. We will do this by advocating for better treatment and care, enhancing quality of life, supporting research and amplifying the patient’s voice.
The focus of our charitable activity since our foundation has been to provide access to specialist nurses at the point of need, in local hospitals across the UK. Mesothelioma Clinical Nurse Specialists provide a large range of benefits including; specialist expertise available to patients, increased access to clinical trials, an increase in the number of patients accessing treatment, a lower rate of unplanned admissions, better management of symptoms and an overall increase in the quality of life for patients.
At Mesothelioma UK, we also provide a number of other services to support anyone affected by mesothelioma. These include a Freephone Support Line, three specialist benefits advisors, a travel grant to support the cost of accessing clinical trials, a dedicated research centre at Sheffield University and a comprehensive information service accredited by the Patient Information Forum. Services such as this helped us directly support 1900 patients or carers in 2020/21 and reach a further ~500 people indirectly.
We understand that people diagnosed with mesothelioma feel very strongly about preventing future cases. That is why we work closely with partner organisations to raise awareness of asbestos and to shine a light on the devastating impact of mesothelioma.

MeVis Medical Solutions AG

MeVis Medical Solutions AG develops software for the analysis and processing of medical imaging data. Focus is the image-based early detection of cancer. Its state-of-the-art software solutions support the image-based early detection of lung cancer with dedicated reading software and how it can be used in lung cancer screening settings.

Mirati Therapeutics

Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.

MSD

At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com/

Novocure Inc.

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields, TTFields. TTFields are electric fields that disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Optellum

‘Optellum is a commercial-stage lung health company providing Artificial Intelligence decision support software that assists physicians in early diagnosis and optimal treatment for their patients. The company was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, when chances of cure are the highest. Optellum’s roadmap extends beyond lung cancer diagnosis and treatment to other deadly diseases of the lungs, including interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Optellum has headquarters at the Oxford Centre for Innovation in Oxford, United Kingdom and a U.S. office at the Texas Medical Center in Houston, TX.
Optellum has received grant funding from InnovateUK, the National Institute for Health Research (NIHR), the NHS AI Lab, The Accelerated Access Collaborative (AAC), MedCity and EIT Health. For more information, visit optellum.com, or follow us LinkedIn and Twitter.’

Pfizer

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Sanofi Genzyme

Since 2007, Sanofi and Regeneron have collaborated to help people with conditions that are often difficult to diagnose and treat, using innovative technology platforms. Sanofi is an innovative global healthcare company that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

Scanlan International, Inc.

Celebrating 100 Years of Excellence ...and Our Journey Continues!
The highest quality surgical instruments have been designed and manufactured by the Scanlan Family since 1921.
Experience the Scanlan Difference at Exhibit #402.

Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com

Takeda

Takeda Oncology is structured to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. Built on a legacy foundation and structured for agility, our leaders have proven experience to drive future growth.
We’ve demonstrated leadership in the treatment of hematologic cancers and solid tumors, and we’re now leveraging that expertise to advance cutting-edge science through multiple platforms, partnerships and therapeutic approaches. We are focused on collaborating with leading scientific teams around the globe to accelerate remarkable innovation, including by leveraging the power of innate immunity to enhance and broaden the impact of immunotherapy.
We complement our deep in-house expertise with a network of symbiotic external partnerships to unlock the most promising science wherever it emerges. We fuel our relationships with academic, biotechnology and pharmaceutical partners with mutual respect, shared knowledge, scientific rigor and agility to find the best way to attack cancer.
We are structured to ensure a tight connection from research to development to commercialization to rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.
Takeda Oncology: We aspire to cure cancer with inspiration from patients and innovation from everywhere.
For more information, visit www.takedaoncology.com

Thermo Fisher Scientific

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner, and safer. Our clinical next-generation sequencing (NGS) division focuses on delivering simple, fast and cost effective NGS technology for a range of applications. We are enabling precision oncology with easily implementable Oncomine™ assays. Our latest development, the Ion Torrent™ Genexus™ system, provides a highly automated end-to-end workflow allowing laboratories to deliver NGS results in as little as one day.

Turning Point Therapeutics (TP)

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Its lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. The company’s current pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC; TPX-0046, targeting RET; and TPX-0131, a next-generation ALK inhibitor. To learn more, visit www.tptherapeutics.com.

Wisepress Ltd

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

For information on exhibit opportunities, please contact:

International Association for the Study of Lung Cancer (IASLC)
CorporateRelations at iaslc.org
Phone: +1 720 598 1951
Fax: +1 720 325 2848




Conference Newsletter
Subscribe to the Newsletter to receive important information about the upcoming Conference.
X